Navigation Links
Human C-reactive protein regulates myeloma tumor cell growth and survival
Date:9/10/2007

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatment.

CRP is a protein that is made in the liver and secreted systemically during the process of inflammation in response to the inflammatory cytokine IL-6. The blood level of CRP is elevated in patients with infections, inflammatory diseases, some cardiovascular diseases, and malignancies including multiple myeloma (MM). Dr. Qing Yi and Dr. Jing Yang from the M.D. Anderson Cancer Center and colleagues designed a series of studies to investigate whether human CRP might influence the growth and survival of MM tumor cells.

The researchers found that addition of CRP to cell cultures at levels observed in patients with MM promoted myeloma cell proliferation and protected myeloma cells from chemotherapy-induced apoptosis and apoptosis induced by IL-6 withdrawal. The protective influence of CRP was also validated in a mouse model of myeloma.

The researchers went on to investigate the cell signaling pathways underlying CRP-mediated protection of myeloma cells. They demonstrated that CRP enhanced secretion of IL-6; binds activating Fcg receptors; activates PI3K/Akt, ERK, and NF-kB pathways; and inhibits caspase cascade activation induced by chemotherapy drugs. Further, CRP was shown to synergize with IL-6 in protecting myeloma cells from apoptosis.

These results provide strong evidence that CRP is not just a marker for MM but is a critical regulator of myeloma cell survival. CRP protects myeloma cells from apoptosis induced by chemotherapy drugs and stimulates myeloma cells to secrets more IL-6, which in turn provides additional protection to myeloma from apoptosis and stimulates liver cells to secrete more CRP. Thus, CRP could be a therapeuti
'/>"/>

Contact: Nancy Wampler
nwampler@cell.com
617-386-2121
Cell Press
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Controversial deal on public access of the human genome map
4. Man against HIV – new vaccine ready for human trials
5. Scientists plan human cloning clinic in the United States
6. Human gene number increases
7. First human clone is near
8. Water regulation in humans
9. Fossil teeth and human development
10. Scientists found ancient Human Germ Killer
11. New standards for Human Research Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...cancer, constipation and other conditions may soon...f using injections.Scientists in India have develo...s to manage diseases that often require an injecti...nfections. The new gel can also prevent problems c...
...combined efforts to determine the potential health...looked at 20 risk factors.// Some of those include... and hygiene, indoor smoke, childhood sexual abuse...7 percent of premature deaths and 39 percent of to...
...al activity of adults with asthma. Knowing if asth...ing could help health professionals in designing f...the Centers for Disease Control and Prevention con...ctivity levels of adults with asthma. The study in...
..., frequent urination or abnormal periods, uterine ...rous // growths found in the uterus and can range ...e or larger. Now, there’s an improvement to uterin...at’s becoming the procedure of choice for many wom...
Other Medicine News:
(Date:9/4/2008)...o Enroll 750 Women at More Than 100 Sites in the U...atRx Pharmaceuticals, a,privately-held biopharmace...alization of compounds to treat endocrine, metabol...hat it has initiated a second,Phase 3 clinical tri...,s,estrogen-free oral therapy in development for t...
(Date:9/4/2008)...Remain on Schedule with Two Abstracts Accepted for... in November 2008, BRIDGEWATER, N.J., Sept. 4 /PR...cialty pharmaceutical company focused on the treat...y announced the appointment of,Peter L. Garrambone... Garrambone,s career includes more than 50 pharmac...
(Date:9/3/2008)... up results from chronically infected Hepatitis C,... obtained earlier in 2008, - Study is the first ... antiviral effect of therapeutic Hepatitis C...upport move into a second generation, vaccine for...hrough TLR activatio...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Male kidneys for men only 3F 23584 1Male kidneys for men only 3F 23584 2U M study 3A Herceptin targets breast cancer stem cells 3963 1U M study 3A Herceptin targets breast cancer stem cells 3963 2Big brains arose twice in higher primates 3959 1Big brains arose twice in higher primates 3959 2ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 1ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 2ACS Forum to Showcase Innovative Healthcare Model for European Union 23578 3
...AILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007...ay announced,preliminary results from two open-lab...g the potential use of Xcytrin(R),(motexafin gadol...date, in combination with Alimta(R) (pemetrexed) a...a second-line treatment,for patients with non-smal...
...N DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The Unive...ed the following study and,press release, "Scienti...t Tissue," June 15, 2007, Science Daily: "Research...cine have successfully,isolated and cultured human...sue, suggesting that they have found another impor...
Other Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 2Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's,Published Study on Culture Blood-Forming Stem Cells from Human Fat,Tissue as Supporting Near Term Benefits of Banking Adipose (Fat),Derived Stem Cells 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: